NCT02285920
Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-Dependent ESRD Trial
See it on ClinicalTrials.gov ↗129 people
34.1%
65.9%
44 womenmiddle line = equal numbers85 men
- Phase
- PHASE2
- Paid for by
- University of Pennsylvania
- Finished
- 2017-07-30
- Health conditions
- End-Stage Renal Disease
- Who could join
- Anyone
- Ages
- 18 Years – 85 Years
- Average age
- mean 55.5 years
- Age 65+
- Not reported
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Black / African American 71.3% · White 20.9% · Asian 3.9% · Not reported 3.9% · American Indian / Alaska Native 0% · Native Hawaiian / Pacific Islander 0% · More than one race 0%
Women left out
- No pregnant women
Women who were pregnant could not join.
“Pregnancy, anticipated pregnancy, or breastfeeding”
- No breastfeeding moms
Women who were breastfeeding could not join.
“Pregnancy, anticipated pregnancy, or breastfeeding”
- Had to use birth control
Women who couldn't or didn't want to use birth control were turned away.
“For women of childbearing potential, willingness to use a highly effective method of birth control for up to 4 weeks after the last dose to study drug.”
Study titles and rules are shown in their original English.